Shelf-life extension program (SLEP) as a significant contributor to Strategic National Stockpile Maintenance: the Israeli experience with ciprofloxacin

Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science
Moran BodasArik Eisenkraft

Abstract

In the past decade, the 2001 anthrax incident in the U.S. and the 2003 SARS epidemic have highlighted the biological threat to civilian populations. The risk posed by the natural or manmade spread of biological agents among the population dictates a need for better national preparedness. One key component of this preparation is the establishment of a Strategic National Stockpile (SNS) of pharmaceuticals that would provide appropriate medical countermeasures in case of an outbreak. However, to reduce the expense of such a stockpile and to make it worthwhile, there is also a need for a shelf-life extension program (SLEP) through which pharmaceuticals could be extended beyond manufacturer-ascribed shelf life, as long as they meet regulation standards. In this article, we review the Israeli experience with the national ciprofloxacin stockpile procurement and shelf-life extension program.

References

Feb 26, 1999·Science·D A Henderson
Oct 8, 1999·Emerging Infectious Diseases·M I MeltzerK Fukuda
Mar 19, 2002·Emerging Infectious Diseases·Lisa D RotzJames M Hughes
Nov 12, 2003·Emerging Infectious Diseases·Anders TegnellGeorgios Gouvras
Apr 8, 2004·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Bengt Sundelius, Jesper Grönvall
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrea MeyerhoffDianne Murphy
May 25, 2006·Journal of Pharmaceutical Sciences·Robbe C LyonAjaz S Hussain
Sep 27, 2006·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Dena M BravataDouglas K Owens
Jul 31, 2008·Journal of Preventive Medicine and Public Health = Yebang Ŭihakhoe Chi·Hyun Soon Hwang
Apr 22, 2009·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Brooke CourtneyChristine SooHoo

❮ Previous
Next ❯

Citations

Aug 19, 2016·Frontiers in Microbiology·Callum J CooperAnders S Nilsson
Mar 24, 2018·Health Security·Terri RebmannSanya Vatwani
Mar 24, 2018·MSphere·Diane DiEuliis, Gigi Kwik Gronvall
Aug 15, 2017·Bulletin of the World Health Organization·Pakoyo Fadhiru KambaBruhan Kaggwa
Nov 18, 2018·Analytica Chimica Acta·Daniel R Willett, Jason D Rodriguez

❮ Previous
Next ❯

Software Mentioned

ICSLEP
SLEP

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Related Papers

Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science
Gregory S ParnellAlyson G Wilson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Philip K Russell
Disaster Management & Response : DMR : an Official Publication of the Emergency Nurses Association
Debraelee Esbitt
The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists
Jeannette Y Wick
© 2021 Meta ULC. All rights reserved